Novo development exec: ”I’m looking at a rich pipeline across all therapy areas"
Pharmaceutical firm Novo Nordisk is heavily expanding when it comes to disease areas and technologies. The man tasked with the job looks ahead to a bright future, while not pre-emptively betting on any specific candidate.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Novo Nordisk is forging a future beyond the patent expiration for its lucrative molecule semaglutide, which is behind the company’s best-selling drug by some distance, diabetes treatment Ozempic, which sold for DKK 33.7bn (USD 5.2bn) in 2021 alone.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk ready to go toe to toe with Ascendis
For subscribers
